366 related articles for article (PubMed ID: 31905715)
1. Advances in the Development of Pharmacological Chaperones for the Mucopolysaccharidoses.
Losada Díaz JC; Cepeda Del Castillo J; Rodriguez-López EA; Alméciga-Díaz CJ
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31905715
[TBL] [Abstract][Full Text] [Related]
2. Characterization of pulmonary function impairments in patients with mucopolysaccharidoses--changes with age and treatment.
Lin SP; Shih SC; Chuang CK; Lee KS; Chen MR; Niu DM; Chiu PC; Lin SJ; Lin HY
Pediatr Pulmonol; 2014 Mar; 49(3):277-84. PubMed ID: 23401495
[TBL] [Abstract][Full Text] [Related]
3. The landscape of Mucopolysaccharidosis in Southern and Eastern European countries: a survey from 19 specialistic centers.
Tylki-Szymańska A; Almássy Z; Christophidou-Anastasiadou V; Avdjieva-Tzavella D; Barisic I; Cerkauskiene R; Cuturilo G; Djiordjevic M; Gucev Z; Hlavata A; Kieć-Wilk B; Magner M; Pecin I; Plaiasu V; Samardzic M; Zafeiriou D; Zaganas I; Lampe C
Orphanet J Rare Dis; 2022 Mar; 17(1):136. PubMed ID: 35331284
[TBL] [Abstract][Full Text] [Related]
4. Enzyme enhancement therapeutics for lysosomal storage diseases: Current status and perspective.
Thomas R; Kermode AR
Mol Genet Metab; 2019 Feb; 126(2):83-97. PubMed ID: 30528228
[TBL] [Abstract][Full Text] [Related]
5. Enzyme replacement therapy for mucopolysaccharidoses; past, present, and future.
Chen HH; Sawamoto K; Mason RW; Kobayashi H; Yamaguchi S; Suzuki Y; Orii K; Orii T; Tomatsu S
J Hum Genet; 2019 Nov; 64(11):1153-1171. PubMed ID: 31455839
[TBL] [Abstract][Full Text] [Related]
6. [Enzyme replacement therapy for mucopolysaccharidoses I, II and VI: recommendations from a group of Brazilian F experts].
Giugliani R; Federhen A; Muñoz Rojas MV; Vieira TA; Artigalás O; Pinto LL; Azevedo AC; Acosta AX; Bomfim C; Lourenço CM; Kim CA; Horovitz D; Souza DB; Norato D; Marinho D; Palhares D; Santos ES; Ribeiro E; Valadares ER; Guarany F; De Lucca GR; Pimentel H; Souza IN; Corrêa Neto J; Fraga JC; Góes JE; Cabral JM; Simeonato J; Llerena JC; Jardim LB; Giuliani Lde R; Silva LC; Santos M; Moreira MA; Kerstenetzky M; Ribeiro M; Ruas N; Barrios P; Aranda P; Honjo R; Boy R; Costa R; Souza CF; Alcântara FF; Avilla SG; Fagondes S; Martins AM
Rev Assoc Med Bras (1992); 2010; 56(3):271-7. PubMed ID: 20676532
[TBL] [Abstract][Full Text] [Related]
7. Chaperone effect of sulfated disaccharide from heparin on mutant iduronate-2-sulfatase in mucopolysaccharidosis type II.
Hoshina H; Shimada Y; Higuchi T; Kobayashi H; Ida H; Ohashi T
Mol Genet Metab; 2018 Feb; 123(2):118-122. PubMed ID: 29289480
[TBL] [Abstract][Full Text] [Related]
8. Carbohydrate-Processing Enzymes of the Lysosome: Diseases Caused by Misfolded Mutants and Sugar Mimetics as Correcting Pharmacological Chaperones.
Stütz AE; Wrodnigg TM
Adv Carbohydr Chem Biochem; 2016; 73():225-302. PubMed ID: 27816107
[TBL] [Abstract][Full Text] [Related]
9. Mucopolysaccharidosis III: Molecular basis and treatment.
Spahiu L; Behluli E; Peterlin B; Nefic H; Hadziselimovic R; Liehr T; Temaj G
Pediatr Endocrinol Diabetes Metab; 2021; 27(3):201-208. PubMed ID: 34743503
[TBL] [Abstract][Full Text] [Related]
10. Mucopolysaccharidoses: Cellular Consequences of Glycosaminoglycans Accumulation and Potential Targets.
Leal AF; Benincore-Flórez E; Rintz E; Herreño-Pachón AM; Celik B; Ago Y; Alméciga-Díaz CJ; Tomatsu S
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613919
[TBL] [Abstract][Full Text] [Related]
11. Newborn screening of mucopolysaccharidoses: past, present, and future.
Arunkumar N; Langan TJ; Stapleton M; Kubaski F; Mason RW; Singh R; Kobayashi H; Yamaguchi S; Suzuki Y; Orii K; Orii T; Fukao T; Tomatsu S
J Hum Genet; 2020 Jul; 65(7):557-567. PubMed ID: 32277174
[TBL] [Abstract][Full Text] [Related]
12. Decreased Levels of Chaperones in Mucopolysaccharidoses and Their Elevation as a Putative Auxiliary Therapeutic Approach.
Żabińska M; Gaffke L; Bielańska P; Podlacha M; Rintz E; Cyske Z; Węgrzyn G; Pierzynowska K
Pharmaceutics; 2023 Feb; 15(2):. PubMed ID: 36840025
[TBL] [Abstract][Full Text] [Related]
13. [Treatment prospects of lysosomal storage disorders].
Reismann P; Tulassay Z
Orv Hetil; 2008 Jun; 149(25):1171-9. PubMed ID: 18547894
[TBL] [Abstract][Full Text] [Related]
14. Substrate accumulation and extracellular matrix remodelling promote persistent upper airway disease in mucopolysaccharidosis patients on enzyme replacement therapy.
Pal AR; Mercer J; Jones SA; Bruce IA; Bigger BW
PLoS One; 2018; 13(9):e0203216. PubMed ID: 30226843
[TBL] [Abstract][Full Text] [Related]
15. Mucopolysaccharidoses and mucolipidoses.
Van Hoof F
J Clin Pathol Suppl (R Coll Pathol); 1974; 8():64-93. PubMed ID: 4220223
[No Abstract] [Full Text] [Related]
16. Pharmacological chaperones as therapeutics for lysosomal storage diseases.
Boyd RE; Lee G; Rybczynski P; Benjamin ER; Khanna R; Wustman BA; Valenzano KJ
J Med Chem; 2013 Apr; 56(7):2705-25. PubMed ID: 23363020
[TBL] [Abstract][Full Text] [Related]
17. Gene expression-targeted isoflavone therapy.
Węgrzyn A
IUBMB Life; 2012 Apr; 64(4):307-15. PubMed ID: 22362546
[TBL] [Abstract][Full Text] [Related]
18. Putative biological mechanisms of efficiency of substrate reduction therapies for mucopolysaccharidoses.
Banecka-Majkutewicz Z; Jakóbkiewicz-Banecka J; Gabig-Cimińska M; Węgrzyn A; Węgrzyn G
Arch Immunol Ther Exp (Warsz); 2012 Dec; 60(6):461-8. PubMed ID: 22949095
[TBL] [Abstract][Full Text] [Related]
19. Identification and characterization of pharmacological chaperones to correct enzyme deficiencies in lysosomal storage disorders.
Valenzano KJ; Khanna R; Powe AC; Boyd R; Lee G; Flanagan JJ; Benjamin ER
Assay Drug Dev Technol; 2011 Jun; 9(3):213-35. PubMed ID: 21612550
[TBL] [Abstract][Full Text] [Related]
20. [Enzyme replacement therapy for lysosomal storage disorders].
Valayannopoulos V; Brassier A; Chabli A; Caillaud C; Lemoine M; Odent T; Arnoux JB; de Lonlay P
Arch Pediatr; 2011 Oct; 18(10):1119-23. PubMed ID: 21873040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
